

Cancer Science Conflict of Interest Policy

The Japanese Cancer Association (JCA) requires authors, editors and reviewers, to disclose any potential conflict of interest related to articles submitted for publication in “Cancer Science”. A conflict of interest exists when anyone has financial or personal relationships that could inappropriately influence (bias) his or her actions. The intent of the JCA Conflict of Interest disclosure policy is to provide authors, editors, and readers with all the facts necessary to make informed judgments about the content of *Cancer Science*.

Authors will be required to complete a conflict of interest disclosure form as part of the initial manuscript submission process. The corresponding author is responsible for obtaining accurate information of conflict of interest forms from all authors of the manuscript. The disclosure of a potential conflict of interest does not necessarily affect the manuscript’s chances of acceptance. Disclosures, only when clearly related to the topic of the present manuscript, will appear as “Disclosure Statement” in the published article. Disclosures that the author deems relevant will be disclosed publicly.

Serious failure by any author to disclose a conflict that later comes to light will result in a ban on the author publishing in Cancer Science for a maximum of 3 years.

Editors are required to fill out conflict of interest disclosure forms on an annual basis. Editors, Associate Editors and persons asked to peer review a manuscript, should voluntarily remove themselves from involvement in any manuscript review or discussion if they believe they could have a conflict of interest.

Guidelines for Authors

- All authors are required to disclose any financial relationship (within the **past 3 years**) with any company or institution that might benefit from the publication of the manuscript, only as it relates to the manuscript you are currently submitting **by uploading “Disclosure Form”**.
- It applies to all authors and their spouse or other immediate family members (spouse, family related in the first degree, or people who share income/property with them).
- Authors might consider, as a guide for financial disclosures, reporting interests where the sums concerned are described in the following JCA’s definition:
 1. With regard to a position as an officer or an advisor (including consultant, etc.) of the Companies, etc., if annual value of remuneration received from a single Company, etc. is 1 million yen or more, a declaration must be made. For spouse, family related in the first degree, or a person sharing income or proprietary interest with the declarer, a declaration is also required if he or she is an employee of the Company.
 2. With regard to share ownership, if the annual profit (the sum of dividends and profit on sale) from shares of a single Company, etc. during a one-year period is 1 million yen or more (in the case of stock options, if the latent profit is 1 million yen or more), or if the total proportion of shares owned in the Company, etc. is 5% or more, a declaration must be made.

3. With regard to patent royalties or transfer gains received from a single Company or for-profit organization, if the total annual value is 1 million yen or more in total, a declaration must be made.
4. With regard to lecture fees, honoraria, or other fees paid by a single Company or for-profit organization for the time or labor of a researcher engaged for conference attendance (as a lecturer, chairperson, ad hoc advisor, etc.), if the total annual value is 500,000 yen or more in total, a declaration must be made.
5. With regard to manuscript fees for a pamphlet, etc. paid by a single Company or for-profit organization, if the total annual value is 500,000 yen or more in total, a declaration must be made.
6. With regard to research funds (joint research funds, contract research funds, clinical trial funds, etc.) provided directly under contracts by a single Company or for-profit organization, or by a non-profit organization funded by the Company, etc., if the total annual value is 1 million yen or more, a declaration must be made.
7. With regard to scholarship (incentive) endowments provided directly from a single Company or for-profit organization, or research grants provided directly from a private academic support organization, if the total annual value is 1 million yen or more, a declaration must be made.
- * State cases where the total annual allocation to the declarer which the declarer can substantially use for whatever purposes he or she chooses, is 1 million yen or more (direct cost)
8. If the declarer belongs to an endowed chair etc. funded by a Company or for-profit organization, or has accepted a researcher, etc. from a Company or for-profit organization where the declarer is a research facility representative, a declaration must be made (a declaration is required regardless of whether or not employment costs are incurred).
9. With regard to remuneration (travel expenses, gifts, etc., that are not directly related to research), if the annual remuneration received from a single Company, etc. is 50,000 yen or more, a declaration must be made.

[UPDATE]

If your paper is regarding a clinical study, you should also disclose the following in the “Disclosure” section:

1. Clinical study conducted/led by an industry (when an industry is responsible for the study).
Example: The study was designed under the responsibility of ABC Corporation, in conjunction with the steering committee.
2. Funding (applicable regardless of amount)
Example: The study was funded by ABC Corporation/Ministry of Health, Labor and Welfare, Japan (Grant No. XXXX)
3. Supply of drugs for experiments
Example: (Study drug) was donated/provided by ABC Corporation.
4. Support provided to collect/analyze data or to write a manuscript
Example: ABC Corporation collected and analyzed the data and contributed to the interpretation of the

study. All authors had full access to all of the data in the study and had final responsibility for the decision to submit for publication.

- When your manuscript is accepted for publication in *Cancer Science*, your statement will appear in your article as “Disclosure Statement” as follows:

Disclosure Statement Example (the underlined text is applicable to clinical studies only)

A (author name) serves as a consultant to Z (entity name); B’s spouse is chairman of Y; C received a research grant from X; D received lecture fees from V; E holds a patent on U; F has been reimbursed by T for attending several conferences; G received honoraria for writing promotional material for S; The study was designed under the responsibility of ABC Corporation, in conjunction with the steering committee; The study was funded by ABC Corporation/Ministry of Health, Labor and Welfare, Japan (Grant No. XXXX); (Study drug) was donated/provided by ABC Corporation; ABC Corporation collected and analyzed the data and contributed to the interpretation of the study. All authors had full access to all of the data in the study and had final responsibility for the decision to submit for publication; H has no conflict of interest.

If there is no relationship relevant to the manuscript’s subject, indicate “The authors have no conflict of interest.”